Increased Number of Mesenchymal Stem Cell-like Cells in Peripheral Blood of Patients with Bone Sarcomas

Background and Aims mber of peripheral blood mesenchymal stem cells (PBMSCs) may increase under pathological conditions. We sought to compare the number of MSC-like cells in the peripheral blood of patients with bone sarcomas with healthy controls and to analyze related cytokines in the peripheral blood plasma. s eral blood mononuclear cells (PBMNs) of patients with bone sarcomas and control subjects were isolated for culture and analyzed by flow cytometry for MSC phenotype. Cytokines in the plasma obtained after cell separation were analyzed using enzyme-linked immunosorbent assay (ELISA). Annexin-V and β-galactosidase staining were used to investigate whether the cells died from apoptosis or senescence. s ytometric analysis demonstrated an >9-fold increase in the number of cells with MSC-like phenotypes (CD34–, CD45–, CD105+) in patients with bone sarcomas compared with control subjects (p <0.05). ELISA results showed that concentrations of hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) in patients with bone sarcomas were statistically higher than those in the control subjects (p <0.05), whereas there was no significant difference in plasma concentrations of leptin and stromal cell-derived factor 1 between the two groups. A significant, positive correlation between the percentages of PBMSC-like cells and concentrations of HGF in all samples (R = 0.618; p = 0.011). Annexin-V staining of MSC-like cells was positive, whereas β-galactosidase staining was negative. sions eral blood of patients with bone sarcomas has more cells with MSC phenotypes than blood of healthy persons. The increased number is accompanied by increased HGF and VEGF in the plasma.